Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-22

Study Completion Date

2023-09-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled study in sickle cell disease participants with a history of Vaso-occlusive Crises (VOCs). Approximately 60 participants with sickle cell disease will be enrolled and randomized: 12 participants in each of four active novel formulation rifaximin groups and 6 participants in each of 2 placebo groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

NCT03264989

Sickle Cell Disease (SCD)

COMPLETED PHASE2

A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

NCT02633397

Sickle Cell Disease

COMPLETED PHASE2

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

NCT02973360

Sickle Cell Disease

UNKNOWN PHASE2

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

NCT03474965

Sickle Cell Disease (SCD)

COMPLETED PHASE2

An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate

NCT02520557

SCAR

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low Dose Rifaximin ER

twice daily

Group Type EXPERIMENTAL

Low Dose Rifaximin ER

Intervention Type DRUG

Low Dose Rifaximin Extended Release Twice Daily

Low Dose Rifaximin DER

twice daily

Group Type EXPERIMENTAL

Low Dose Rifaximin DER

Intervention Type DRUG

Low Dose Rifaximin Delayed Extended Release Twice Daily

High Dose Rifaximin ER

twice daily

Group Type EXPERIMENTAL

High Dose Rifaximin ER

Intervention Type DRUG

High Dose Rifaximin Extended Release Twice Daily

High Dose Rifaximin DER

twice daily

Group Type EXPERIMENTAL

High Dose Rifaximin DER

Intervention Type DRUG

High Dose Rifaximin Delayed Extended Release Twice Daily

Placebo

twice daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo Twice Daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low Dose Rifaximin ER

Low Dose Rifaximin Extended Release Twice Daily

Intervention Type DRUG

Low Dose Rifaximin DER

Low Dose Rifaximin Delayed Extended Release Twice Daily

Intervention Type DRUG

High Dose Rifaximin ER

High Dose Rifaximin Extended Release Twice Daily

Intervention Type DRUG

High Dose Rifaximin DER

High Dose Rifaximin Delayed Extended Release Twice Daily

Intervention Type DRUG

Placebo

Placebo Twice Daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ability and willingness to sign a written informed consent form.
2. between the ages of 18 to 70 years old (inclusive) at the time of consent.
3. SCD of any genotype (HbSS, HbSC, HbS β-thalassemia). If the subject's genotype has not been previously documented, genotyping will be performed during Screening using high-performance liquid chromatography (HPLC)/electrophoresis.
4. least 2 VOCs within the 12 months prior to Screening.
5. if receiving hydroxyurea (HU)/hydroxycarbamide (HC), subject must have been receiving the treatment for at least 6 months prior to Screening and must agree to maintain the same dose and schedule for the duration of the study.
6. must have laboratory values at Screening as follows:

1. Absolute Neutrophil Count ≥1.0 x 109/L
2. Platelets ≥ 75 x 109/L
3. Hemoglobin (Hgb) ≥ 6.0 g/dL
4. Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73 m2 using the CKD-EPI formula
5. Total bilirubin ≤ 15 mg/dL
6. Alanine transaminase (ALT) ≤ 3.0 x ULN
7. International Normalized Ratio (INR) ≤ 2.0
7. Eastern Cooperate Oncology Group (ECOG) performance status ≤ 2
8. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must have a negative serum pregnancy test at Screening and agree to use standard prevention methods for the duration of the study.

Exclusion Criteria

1. receiving concomitant treatment with voxelotor, crizanlizumab, or L-glutamine.
2. any history of stem cell transplant, is planning to begin or has received in past 30 days.
3. acute VOC, requiring a visit to a medical facility and/or healthcare professional, ending within 7 days prior to Day 1 dosing.
4. has received any blood products within 30 days prior to Day 1 dosing.
5. uncontrolled liver disease or renal impairment, ulcerative colitis, Crohn's disease, or other chronic GI disorder.
6. has received active treatment in another investigational trial within 30 days or 5 half-lives of the last dose of the investigational agent, whichever is greater, prior to Screening.
7. has received penicillin prophylaxis or antibiotics for treatment of infection within 30 days or 5 half-lives of the treatment, whichever is greater, prior to Screening.
8. significant medical condition that required hospitalization (other than for a VOC) within 2 months prior to Screening.
9. planning on undergoing an exchange transfusion during the duration of the study or has completed one within 4 weeks prior to Day 1 dosing.
10. hypersensitivity to rifaximin, rifampin, rifamycin antimicrobial agents, or any components of rifaximin ER and DER.
11. pregnant or a nursing woman.
12. history of illicit drug use or abuse, either documented or in the opinion of the Investigator.
13. using any medication that is known to inhibit or induce CYP3A4, or P-gp and OATP1B1/B3 within 30 days or 5 half-lives, whichever is longer, prior to Day 1 dosing, or in the opinion of the Investigator, may affect the evaluation of the study product or place the subject at undue risk.
14. has had any prior gastrointestinal surgery which has altered the anatomy of the esophagus, stomach, or small/large intestine (with the exception of appendectomy, cholecystectomy, and fundoplication).
15. has had a colonoscopy or sigmoidoscopy within 30 days prior to Day 1 or plans to undergo such a procedure during the duration of the study.
16. has used bowel prep, laxative, or enema within 30 days prior to Day 1.
17. bleeding disorder including, but not limited to, acquired or congenital platelet function defects, disseminated intravascular coagulation (DIC), bleeding factor deficiencies, hemophilia, idiopathic thrombocytopenia purpura (ITP), or von Willebrand's disease.
18. planning to undergo a major surgical procedure during the duration of the study.
19. positive test for human immunodeficiency virus (HIV)1 or HIV2.
20. active Hepatitis B infection (HBsAg positive). Prior infection that is not active (i.e., HBsAg negative, HBcAb positive, and HBsAb positive) is permitted.
21. positive test for Hepatitis C (HCV RNA). Prior infection with spontaneous resolution or sustained resolution for ≥ 24 weeks after cessation of antivirals is permitted.
22. active COVID-19 infection or complication(s) related to COVID 19 infection that are unresolved or, in the opinion of the Investigator, may affect evaluation of the study drug or place the subject at undue risk.
23. received a vaccine (including COVID-19 vaccine) within 2 weeks prior to Screening. If subject has received their first of two COVID-19 vaccination doses, as applicable, they must wait for at least 2 weeks after receiving the second dose, and be symptom-free, prior to beginning Screening. Subject must not be planning for COVID-19 or other vaccinations while on study.
24. malignant disease. Exceptions include malignancies that were treated curatively and have not recurred within 2 years prior to study treatment, completely resected basal cell and squamous cell skin cancers, and any completely resected carcinoma in situ.
25. prolonged QT interval as assessed by ECG history within the past 3 months. For subjects with no historical ECG information, subject has a resting QTcF ≥ 460 msec for males and ≥ 470 msec for females at Screening.
26. any unstable cardiac condition that, in the opinion of the Investigator, may worsen during the study or interfere with successful evaluation of the study treatment.
27. serious mental or physical illness which, in the opinion of the Investigator, would compromise participation in the study.
28. any condition which, in the opinion of the Investigator, is likely to interfere with the successful collection of the measurements required for the study.
29. unable to understand or comply with study instructions and requirements.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No